Skip to main content
Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Thoracic and cutaneous sarcoid-like reaction associated with anti-PD-1 therapy: longitudinal monitoring of PD-1 and PD-L1 expression after stopping treatment

Fig. 4

Analysis of PD-L1 and PD-1 expression on PBMC. PD-L1 (a) and PD-1 (b) expression was analyzed by flow cytometry on monocytes (CD14+ CD3 CD19), B cells (CD19+ CD14 CD3), CD4+ T cells (CD3+ CD4+ CD8 CD19 CD14) and CD8+ T cells (CD3+ CD8+ CD4 CD19 CD14) from the index case and from control patients at different times after the nivolumab treatment was stopped. Results are expressed as relative fluorescence intensity (RFI) defined as the ratio of specific fluorescence (median fluorescence of cells incubated with the anti-PD-L1 or anti-PD-1 Abs) over non-specific fluorescence (median fluorescence of cells incubated with the isotype control Ab). Each value from the time course analysis of the patients is plotted. The grey area represents the 95% confidence interval of the level of PD-L1 or PD-1 expression on cells from 8 healthy subjects. Inserts, flow cytometry histograms for a representative control patient (left panels) and for the index case patient (right panels, climax of the PD-L1 expression)

Back to article page